Wedbush Rates Immunome (IMNM) buy, $31 Price Target

Analyst David Nierengarten reaffirmed his buy rating on the biotech firm as it continues clinical trials for cancer treatments, a 67.30% upside from the current price.

By EarningsIQ Research Desk · Published Jun 13, 2026, 2:06 AM EDT · Updated Jun 18, 2026, 8:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Wedbush rated Immunome, Inc. ($IMNM) "buy" with a $31 price target on June 12, 2026.

Since the rating, $IMNM is up 4.3% after 1 week, up 24.1% after 1 month and down 10.4% to date (from the $18.38 close on Jun 12, 2026).

IMNM Immunome, Inc.

$16.47 -20.89% year to date

Daily close · Oct 16, 2026

Key Points

Wedbush analyst David Nierengarten reiterated a buy rating on Immunome, Inc. (IMNM) on June 12, 2026, setting a price target of $31.00.
Wedbush's $31 price target implies 67.30% upside from Immunome, Inc.'s ($IMNM) current $18.53 share price.
The stock was trading around $18.53 on Saturday, sitting below its 50-day moving average of $25.30 but well above its 52-week low of $9.85.
Chief Medical Officer Robert Lechleider recently showed confidence in the company by purchasing 55,000 shares at $8.73 each on June 25, 2026.

Get $IMNM trade alerts by text

We text you when insiders, Congress or big funds trade $IMNM. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Immunome, Inc. alert may contain errors. Disclosures

On June 12, 2026, Wedbush analyst David Nierengarten reiterated a buy rating for Immunome, Inc. (IMNM) on the NasdaqCM. The firm set a price target of $31.00 for the biotechnology company, suggesting a significant gap between the current market price and the analyst's expected value. This rating comes as Immunome continues to push its oncology pipeline through various stages of clinical testing.

Analysts Set New Price Targets

Several Wall Street firms have weighed in on Immunome lately. On October 16, 2026, William Blair initiated coverage with an Outperform rating. Earlier, on October 1, 2026, Stifel started the stock with a Hold rating and a $24.00 price target. Alliance Global Partners also began coverage on September 21, 2026, with a buy rating and a $32.00 target. Other firms have been even more optimistic; HC Wainwright & Co. reiterated a buy rating with a $40.00 target on September 10, 2026, and Truist Securities maintained its buy rating with a $38.00 target on August 12, 2026. Overall, the consensus among 14 analysts is a strong buy, with an average price target of $36.00.

Immunome Stock Performance

Shares of Immunome were priced at $18.53 this Saturday. The stock has experienced a wide range over the last year, hitting a high of $30.06 and a low of $9.85. Currently, the price is trading below its 50-day moving average of $25.30 and its 200-day moving average of $22.65. While the company is not yet profitable and does not have a meaningful P/E ratio, it maintains a strong liquidity position with a current ratio of 15.08, which helps fund its expensive drug development programs.

12-month forecast

$IMNM price target

Immunome, Inc. daily closes and this analyst's $31 target. Not advice.

Insider Buying and Selling at Immunome, Inc.

Internal confidence seems to be growing among the leadership team. On June 25, 2026, Chief Medical Officer Robert Lechleider purchased 55,000 shares of Immunome stock at an average price of $8.73 per share. This transaction was valued at roughly $480,150. On the same day, Lechleider was also involved in a separate transaction involving 55,000 shares, though that specific filing did not list a market price or total value.

Oncology Drug Development

Immunome is a biotechnology company based in Bothell, Washington, that focuses on finding and developing new ways to treat cancer. Its most advanced project is Varegacestat, which is currently in Phase 3 clinical trials for desmoid tumors. They are also working on antibody-drug conjugates, which are like guided missiles designed to kill cancer cells while leaving healthy ones alone. The company’s ability to move these drugs through the FDA pipeline is a major factor in how analysts value the stock.

Future Outlook

Investors are looking ahead to Immunome’s next financial update, which is expected on November 5, 2026. Because the company is in the clinical stage, it does not pay a dividend and instead reinvests its cash into research and development. The current cash-to-debt ratio remains healthy, but like most biotech firms, its stock price will likely remain sensitive to trial results and regulatory news from the FDA.